-
The founding CEO of Cornerstone Pharmaceuticals joined traditional pharmaceutical companies, is Biotech not fragrant?
Time of Update: 2023-02-01
5 billion), and as of the end of December 2021, the number of 18A listed companies has exceeded 45, covering fields from the original biotechnology to medical devices, vaccines and IVDs. At that time, investment institutions also increased their support for the listing and financing of Biotech, including the loss of performance for many years, but many Biotechs have not turned a profit, and even faced many challenges such as tight cash flow and commercialization difficulties.
-
On November 11, the closing limit pool, now this pharmaceutical stock!
Time of Update: 2023-01-06
According to data from the Oriental Wealth Network Market Information Center, the stocks in the limit pool on November 11 mainly came from the Web 3. 0, tourism, medicine and other sectors. Among them
-
On November 11, the closing limit pool, now this pharmaceutical stock!
Time of Update: 2023-01-06
According to data from the Oriental Wealth Network Market Information Center, the stocks in the limit pool on November 11 mainly came from the Web 3. 0, tourism, medicine and other sectors. Among them
-
IPO Application! In the next two weeks, the pharmaceutical stock will strike
Time of Update: 2023-01-06
On November 10, Dongxing Medical issued shares for the first time and listed on the Growth Enterprise Market (GEM) announced that the application date of this offline issuance was the same as the online application date on November 21, with a total of 25,043,334 shares, accounting for no less than 25% of the total share capital after the issuance, all of which were new shares.
-
IPO Application! In the next two weeks, the pharmaceutical stock will strike
Time of Update: 2023-01-06
On November 10, Dongxing Medical issued shares for the first time and listed on the Growth Enterprise Market (GEM) announced that the application date of this offline issuance was the same as the online application date on November 21, with a total of 25,043,334 shares, accounting for no less than 25% of the total share capital after the issuance, all of which were new shares.
-
The spread of multiple respiratory viruses has intensified, and the US healthcare system is under pressure
Time of Update: 2023-01-06
rates among children and the In addition to influenza, the number of respiratory syncytial virus infection cases and the number of emergency department visits and hospitalizations in many places in the United States are on the rise.
-
The spread of multiple respiratory viruses has intensified, and the US healthcare system is under pressure
Time of Update: 2023-01-06
rates among children and the In addition to influenza, the number of respiratory syncytial virus infection cases and the number of emergency department visits and hospitalizations in many places in the United States are on the rise.
-
Since October, the pharmaceutical sector has risen sharply, and the share price of these stocks has doubled
Time of Update: 2023-01-06
In terms of individual stocks, the shares of Zhongsheng Pharmaceutical and Huasen Pharmaceutical doubled, and CanSino, Microelectrophysiology, Shuangcheng Pharmaceutical, and Yiling Pharmaceutical rose by more than 50%.
-
What enlightenment does the new policy bring to the upstream pharmaceutical equipment industry if it severely reduces the "pseudo-innovation" of domestic innovative drugs?
Time of Update: 2023-01-06
After more than a year of adjustment, the innovative drug sector has finally ushered in a rebound since this year's National Day. In July 2021, the Center for Drug Review and Approval (CDE) of the Sta
-
What enlightenment does the new policy bring to the upstream pharmaceutical equipment industry if it severely reduces the "pseudo-innovation" of domestic innovative drugs?
Time of Update: 2023-01-06
After more than a year of adjustment, the innovative drug sector has finally ushered in a rebound since this year's National Day. In July 2021, the Center for Drug Review and Approval (CDE) of the Sta
-
The demand for pharmaceutical glass replacement is large, and the battle for domestic enterprises has begun!
Time of Update: 2023-01-06
News on November 7, Ancai Hi-Tech replied to investors on the interactive platform that after the two phases of the pharmaceutical glass project in the company's Anyang base are put into operation, the annual production capacity is expected to be 10,000 tons.
-
The pattern of the innovative drug industry has become clearer, and there are three points in the layout logic
Time of Update: 2023-01-06
The industry believes that the core of medical insurance is still to encourage innovation, and since the national policy of supporting the development of innovative drugs in 2015, some domestic innovative drugs that appeared in 2018-2019 are some generic innovations that lack special value.
-
In order to achieve import substitution, pharmaceutical enterprises are constantly strengthening independent research and development
Time of Update: 2023-01-06
It is reported that after the landing of Dongfulongding's additional fundraising and investment project, it can extend the company's industrial chain, build an integrated industrial ecology of CGT (cell and gene therapy) pharmaceutical equipment, instruments and consumables, change the market pattern dominated by the import of some CGT pharmaceutical equipment, seize the opportunity of import substitution, and continuously increase market share in key areas.
-
Since October, the pharmaceutical sector has risen sharply, and the share price of these stocks has doubled
Time of Update: 2023-01-06
In terms of individual stocks, the shares of Zhongsheng Pharmaceutical and Huasen Pharmaceutical doubled, and CanSino, Microelectrophysiology, Shuangcheng Pharmaceutical, and Yiling Pharmaceutical rose by more than 50%.
-
The concept of traditional Chinese medicine is active! Many stocks closed with a limit of gains, with individual stocks rising 29 times in the past year
Time of Update: 2023-01-06
According to the data, Longjin Pharmaceutical is a pharmaceutical company engaged in the research and development, production and sales of modern traditional Chinese medicine and characteristic chemical generic drugs.
-
The concept of traditional Chinese medicine is active! Many stocks closed with a limit of gains, with individual stocks rising 29 times in the past year
Time of Update: 2023-01-06
According to the data, Longjin Pharmaceutical is a pharmaceutical company engaged in the research and development, production and sales of modern traditional Chinese medicine and characteristic chemical generic drugs.
-
The pattern of the innovative drug industry has become clearer, and there are three points in the layout logic
Time of Update: 2023-01-06
The industry believes that the core of medical insurance is still to encourage innovation, and since the national policy of supporting the development of innovative drugs in 2015, some domestic innovative drugs that appeared in 2018-2019 are some generic innovations that lack special value.
-
16 pharmaceutical stocks surveyed by institutions (with list)
Time of Update: 2023-01-06
Zhifei Biotech said in the survey that in the first three quarters of this year, the company's business development momentum was good, achieving operating income of 27.
-
16 pharmaceutical stocks surveyed by institutions (with list)
Time of Update: 2023-01-06
Zhifei Biotech said in the survey that in the first three quarters of this year, the company's business development momentum was good, achieving operating income of 27.
-
The demand for pharmaceutical glass replacement is large, and the battle for domestic enterprises has begun!
Time of Update: 2023-01-06
News on November 7, Ancai Hi-Tech replied to investors on the interactive platform that after the two phases of the pharmaceutical glass project in the company's Anyang base are put into operation, the annual production capacity is expected to be 10,000 tons.
